CYR-064 Safety Win Masks Incomplete Efficacy Story: Age-Stratified Signal Demands Scrutiny

Cyrano's CYR-064 Phase II FLAVOR Study Meets Primary Safety Endpoint

Cyrano Therapeutics announced that its Phase II FLAVOR study of CYR-064 successfully met its primary safety endpoint in patients suffering from persistent post-viral loss of smell (hyposmia). The placebo-controlled, double-blind, randomised trial enrolled 151 participants across 14 clinical sites in the US. The study reported no serious adverse events linked to the treatment, with overall adverse event rates similar between the CYR-064 and placebo groups. Efficacy was notably observed in participants under 60 years old, who comprised 66% of the trial population, demonstrating statistically significant gains in smell function over 24 weeks compared to placebo on two patient-reported assessments.

• The FLAVOR study confirmed the favorable safety profile of CYR-064, meeting its primary safety endpoint with no serious adverse events attributed to the treatment. The overall incidence of adverse events was comparable between the active treatment arm and the placebo group, reinforcing the drug's tolerability in patients with post-viral smell loss.
• Significant efficacy was demonstrated in a key subgroup of participants under 60 years of age, representing 66% of the total trial population. In this subgroup, a high dose of CYR-064 led to statistically significant improvements in smell function over 24 weeks, as measured by both the 0-3 Visual Rating Scale (0.72 points improvement vs. 0.12 for placebo) and the 0-10 Numerical Rating Scale (2.08 points improvement vs. 0.68 for placebo).
• CYR-064 is an intranasal theophylline spray that functions as a broad-spectrum phosphodiesterase inhibitor, utilizing a patented delivery system to stimulate olfactory neurons. Following these positive Phase II results, Cyrano Therapeutics plans to advance CYR-064 into Phase III development, aiming to address a substantial global market with a significant unmet need for an approved pharmaceutical therapy for persistent post-viral smell loss.

FLAVOR Study: CYR-064 Meets Safety and Efficacy Endpoints

Recent clinical investigation into persistent post-viral olfactory dysfunction has yielded a growing body of evidence supporting platelet-rich plasma (PRP) as an emerging intervention, with several studies reporting meaningful psychophysical improvements alongside a manageable safety profile.

• "The use of platelet-rich plasma in treatment of olfactory dysfunction: A pilot study" — Intervention: Single intranasal PRP injection into the olfactory cleft mucosa. Seven patients with hyposmia (TDI > 16 but < 30) of greater than 6 months' duration were enrolled. At 3-month follow-up, 60% of hyposmic patients achieved normosmia (TDI > 30), with a mean TDI improvement of 5.85 points; the threshold subcomponent showed the most significant gain. Patients with functional anosmia (TDI < 16) did not improve significantly. No adverse outcomes from intranasal PRP injections were reported.

• "Platelet-rich plasma injection in the olfactory clefts of COVID-19 patients with long-term olfactory dysfunction" (2023) — Intervention: Single PRP injection into the olfactory clefts. Eighty-seven patients (anosmia, hyposmia, or parosmia; mean OD duration 15.7 months) were enrolled. Among the 37 patients assessed at 2 months post-injection, mean ODQ and TDI scores significantly improved from baseline (p < 0.01), with olfactory improvement occurring after a mean of 3.6 ± 1.9 weeks. Adverse events included transient epistaxis (n = 31), parosmia related to xylocaine spray (n = 10), and vasovagal episode (n = 2); the procedure was rated somewhat or moderately painful by 47% and 25% of patients, respectively.

• "Effectiveness of Platelet-Rich Plasma for COVID-19-Related Olfactory Dysfunction: A Controlled Study" (2023) — Intervention: PRP injection into the olfactory clefts vs. untreated controls. Eighty-one PRP patients and 78 controls were included. At 10 weeks post-injection, TDI sub- and total scores significantly increased in the PRP group, and 80.3% of PRP patients reported subjective smell improvement after a mean of 3.4 ± 1.9 weeks. The 10-week TDI and ODQ scores were significantly better in the PRP group compared with controls.

• "Effectiveness of Multiple Platelet-Rich Plasma Injections for Olfactory Dysfunction" — Intervention: Two PRP injections into the olfactory clefts at 4- to 6-month intervals. Eighty-three subjects completed evaluations (anosmia, hyposmia, and parosmia; mean OD duration 49.1 ± 46.9 months). TDI significantly increased after both the first and second injections across all OD subgroups; minimal clinically important difference (MCID) was achieved in 49.4% after the first injection and in 63 cases (75.9%) from baseline to final evaluation. Transient epistaxis was the primary adverse event (46.2%), and no severe adverse events were reported.

• "Clinical Improvement and Immune Signatures Following Platelet-Rich Plasma Therapy for Post-Viral Olfactory Dysfunction" — Intervention: Single bilateral PRP injection into the olfactory clefts. Seventeen subjects with post-viral olfactory dysfunction (PVOD) of ≥ 6 months refractory to standard therapies completed follow-up (mean baseline UPSIT 19; median PVOD duration 27 months). At a mean follow-up of 45 days, 47% reported subjective improvement and 53% achieved minimal clinically important difference; mean UPSIT improved by +3.1 points (SD 6.0). Proteomic analysis identified responder-specific increases in oncostatin M (OSM) and greater reductions in IL-17F, alongside within-subject increases in VEGFA and decreases in IL-6 and IL-33, suggesting coordinated immune remodeling.

Addressing the Significant Unmet Need in Post-Viral Smell Loss

Persistent post-viral hyposmia presents a substantial therapeutic challenge, with current interventions demonstrating only partial efficacy and a meaningful proportion of patients experiencing prolonged or incomplete recovery. A four-year follow-up study found that while 92.3% of patients recovered olfaction, a subset continued to experience hyposmia, with recovery described as "slow, constant and meaningful improvement over years." The complexity of underlying pathophysiology — spanning sustentacular cell infection, OSN ciliary damage, neuroinflammation, and disrupted olfactory signaling — further complicates the development of targeted therapies.

• Limited efficacy of intranasal corticosteroids for post-viral hyposmia: A multicentric randomized controlled superiority trial (NCT04361474, n = 123) evaluating local budesonide nasal irrigation plus olfactory rehabilitation versus olfactory rehabilitation alone in non-severe COVID-19 patients with persistent hyposmia found no statistically significant difference between groups on the primary endpoint (percentage of patients improving >2 points on the ODORATEST score after 30 days; P = 0.5). Local budesonide efficacy was not demonstrated for persistent hyposmia related to COVID-19.

• Incomplete recovery with anti-neuroinflammatory regimens: A clinical study evaluating co-ultramicronized palmitoylethanolamide with luteolin (um-PEA-LUT) plus olfactory training found that approximately 15% of treated patients did not achieve full recovery of a normal olfactory threshold, and almost 5% had no recovery at all, underscoring the existence of a refractory patient population unresponsive to current standard approaches.

• Poor adherence to olfactory training undermines outcomes: The recommended standard-of-care treatment — olfactory training with odor containers twice daily for several weeks — suffers from generally low adherence. In a randomized controlled trial (N = 116), the standard care group had a dropout rate of 23.2%, compared to 6.7% in a nasal insert group, with the nasal insert group also demonstrating significantly higher adherence even after exclusion of dropouts. Reduced adherence directly limits the real-world effectiveness of the primary non-pharmacological intervention.

• Prognostic heterogeneity limits treatment stratification: Younger age and participation in olfactory training were identified as favourable prognostic factors for long-term olfactory recovery, yet no validated clinical tools currently exist to prospectively stratify patients by recovery likelihood or to guide escalation to more intensive therapies. This limits the ability of clinical teams to individualize treatment pathways.

• Absence of established disease-modifying therapy (DMT) options: Disease-modifying therapies used in autoimmune neuroinflammation (e.g., IFN-beta, glatiramer acetate) have not been formally studied for refractory post-COVID-19 smell disorder, despite preliminary comparative data suggesting patients with multiple sclerosis treated with DMTs showed lower severity of persistent olfactory loss than post-COVID-19 patients treated with um-PEA-LUT. Prospective trials investigating DMTs for refractory post-viral olfactory loss have yet to be conducted.

CYR-064: A Promising Step for Post-Viral Smell Loss

The recent Phase II FLAVOR study results for Cyrano Therapeutics' CYR-064 offer a significant glimmer of hope for the millions suffering from persistent post-viral loss of smell, or hyposmia. This condition, often a lingering consequence of infections like COVID-19, extends beyond a mere inconvenience, profoundly impacting daily life, food enjoyment, and even leading to psychological distress. The study's success in meeting its primary safety endpoint, with adverse event rates mirroring placebo, is a critical foundation. For a condition that is debilitating but not life-threatening, a favorable safety profile is paramount for any potential long-term treatment.

What truly stands out is the statistically significant improvement in smell function observed in participants under 60 years old, as measured by patient-reported assessments over 24 weeks. This suggests a targeted therapeutic effect within a specific demographic, potentially guiding future development towards a younger patient population. This age-specific efficacy could be a strategic differentiator, allowing Cyrano to carve out a niche in a market currently underserved by highly effective and safe options. Existing treatments, such as topical corticosteroids or intranasal theophylline, offer varying degrees of benefit and may come with side effects or require specific application techniques.

However, the data also presents important considerations. The absence of reported efficacy in participants aged 60 and older highlights a potential limitation, as olfactory dysfunction is known to increase with age and affects a substantial older population. Future research will need to explore whether different dosing, formulations, or patient selection criteria could extend the benefits to this demographic. Furthermore, while the safety profile is excellent, the drug's comparative efficacy against current best practices, including intensive olfactory training, will be crucial for widespread adoption and reimbursement. The 24-week data is encouraging, but long-term durability and its applicability to other causes of smell loss beyond post-viral etiologies will also be key areas for future investigation. This initial success, nonetheless, marks a positive stride towards addressing a widespread and often overlooked medical challenge.